Šagud, Marina; Nikolac, Matea; Mihaljević-Peleš, Alma; Nedić, Gordana; Vuksan Ćusa, Bjanka; Mustapić, Maja; Jakovljević, Miro; Muck-Šeler, Dorotea; Pivac, Nela
The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients, Letter to the Editors.
Rationale Ziprasidone is an atypical antipsychotic, with the unique multireceptor-binding profile. If affects multiple serotonergic (5-HT) receptors, inhibits 5-HT transporter (5-HTT) and inhibits synaptic 5-HT reuptake. These effects might be responsible for the antidepressant effect of ziprasidone. Objectives Since there is a lack of in vivo data on the effects of ziprasidone on 5-HT concentration in humans, the aim of the study was to investigate the effect of ziprasidone treatment on platelet 5-HT concentration in patients with schizophrenia or schizoaffective disorders. Methods In and open-label study, the effect of ziprasidone (average dose of 109 mg/day) on platelet 5-HT concentration (determined fluorimetrically) was evaluated at baseline and after 7 and 28 days of treatment in 21 male and female patients with schizophrenia or schizoaffective disorders. Results Ziprasidone treatment for 7 or 28 days did not significantly change baseline platelet 5-HT concentration in male and female schizophrenic patients. Platelet 5-HT concentration was not correlated with gender, age and smoking status of patients. Conclusions There was a lack of effect of ziprasidone treatment on platelet 5-HT concentration in male and female schizophrenic patients. Although the clinical effects of ziprasidone were evident after 28 days of treatment, and ziprasidone has the highest potency among atypical antipsychotics to block 5-HTT, our data did not confirm the hypothesis that ziprasidone treatment decreases platelet 5-HT concentration, at least not in the doses used in our study.
||Ziprasidone; platelet serotoni; schizophrenia; male and female patients
||BIOMEDICINE AND HEALTHCARE > Clinical Medical Sciences
||Division of Molecular Medicine
|Project title||Project leader||Project code||Project type|
|Molecular basis and treatment of psychiatric and stress related disorders (Molekularna podloga i liječenje psihijatrijskih i stresom izazvanih poremećaja)-||Nela Pivac||098-0982522-2455||MZOS|
|Pharmacogenomics and proteomics of serotonergic and catecholaminergic system (Farmakogenomika i proteomika serotoninskog i kateholaminskog sustava)-||Dorotea Muck-Šeler||098-0982522-2457||MZOS|
|Pharmacogenetic varability of psychiatric patients (Farmakogenetska varijabilnost u psihijatrijskih bolesnika)-||Alma Mihaljević-Peleš||108-1083509-3513||MZOS|
|Multidimensional analysis of bilogical markers in mental disorders (Multidimenzionalna analiza bioloških pokazatelja u duševnim poremećajima)-||Miro Jakovljević||108-1080037-0323||MZOS|
Matea Nikolac Perković
||02 Dec 2015 17:09
||02 Dec 2015 17:09
Actions (login required)